Canada: Proposed Canadian Amendments Will Affect Innovative Drug Companies

Last Updated: October 21 2005

By Conor McCourt

This article first appeared in the May/June 2005 issue of Update. Reprinted with the permission of the Food and Drug Law Institute (FDLI) © 2005.

The government of Canada recently published proposed amendments1 to the Patented Medicines (Notice of Compliance) Regulations2 and to the Food and Drug Regulations3 that will affect innovative drug companies. These regulations create the regulatory framework that, together with patent enforcement proceedings under Canada’s Patent Act,4 governs the protection of pharmaceutical patents. The proposed amendments seek to alter this regulatory framework as follows:

  • restricting the application of the Patented Medicine (Notice of Compliance) Regulations, most notably by limiting an innovator’s ability to list and enforce patents on the patent register maintained by the Minister of Health; and
  • enhancing protection for the data that an innovator is required to submit to the Minister of Health as part of its new drug submission, and extending the period of data protection from five to eight years (eight and a half years for pediatric studies).

Changes to the Patented Medicines (Notice of Compliance) Regulations

The Patented Medicines (Notice of Compliance) Regulations permit an innovator that files a new drug submission or supplementary new drug submission to submit certain patents for inclusion on the patent register. The patent register lists patents for medicinal products that have been approved by the Minister of Health for sale in Canada.

Listed patents are afforded certain protections. When a generic pharmaceutical company seeks marketing approval for its product by comparing it to an innovator’s reference product for which there is a listed patent, the generic manufacturer must either accept the fact that marketing approval of its product cannot be issued until the listed patent expires or serve the innovator with a notice of allegation. That notice must specify why the listed patent should not prevent the generic competitor from marketing its product before the expiry of the listed patent. The Patented Medicines (Notice of Compliance) Regulations permit the innovator to commence legal proceedings in response to the notice of allegation. The proceedings trigger an automatic stay of marketing approval for the generic product for up to 24 months.

The proposed amendments to the Patented Medicines (Notice of Compliance) Regulations will change the regime in three important ways.

First, the proposed amendments would restrict the type of patents that may be listed on the patent register. Currently, patents are eligible for inclusion on the patent register if they contain claims for the medicine contained in the product for which approval is sought; claims to formulations containing that medicine; and claims for indications involving the medicine. Moreover, under the current regime, a patent that relates to a formulation that is different from the approved product is still eligible for listing, as is a patent that claims an off-label indication.

Furthermore, the proposed amendments would restrict the type of patents listed on the patent register to those that include claims to the compound, formulation, or indication for which approval is sought—in other words, to patents that cover the approved product. For practical purposes, this amendment would have the most serious impact on patents that until now have been eligible for inclusion on the patent register in connection with supplementary new drug submissions. In addition, certain types of supplementary new drug submissions in respect of which patents can be listed have been excluded from the operation of the Patented Medicines (Notice of Compliance) Regulations. These excluded supplementary new drug submissions are those seeking approval for 1) brand name changes; 2) manufacturing site changes; 3) process changes; 4) quality control (specification) changes; 5) label changes; 6) dosage form changes; 7) safety profile changes; and 8) withdrawal period amendments. Basically, this leaves only supplementary new drug submissions that relate to new formulations or indications as being included.

Second, the proposed amendments would alter the existing requirement that a generic competitor must address all patents listed on the patent register, including newly added patents. Under the proposed amendments, a generic competitor would have to address a newly added patent only if it were added in relation to an innovator’s supplementary new drug submission, and then only if that submission were filed prior to the filing of a generic competitor’s request for marketing approval of its product.

Third, the proposed amendments would expand the type of allegation that a generic competitor may make in a notice of allegation. At present, a generic competitor typically will allege that its proposed product will not infringe the listed patent and/or that the listed patent is invalid. The proposed amendments would permit a generic competitor to make two additional allegations: 1) that the innovator has falsely certified a patent’s eligibility for inclusion on the patent register; and 2) that in the case of a patent listed against a supplementary new drug submission for a new use, the generic competitor is not seeking approval for the claimed use.

The proposed amendments contain both an anti-avoidance provision and a grandfathering provision. Under the anti-avoidance provision, an innovator that withdraws its original approved product to prevent generic competitors from using it as comparison will lose the protection of the Patented Medicines (Notice of Compliance) Regulations for all patents listed on the patent register for that approved medicine.

The grandfathering provision stipulates that patents on the patent register as of the date the amendments come into force will remain on the register and will be subject to the listing requirements as they existed prior to that date.

Enhanced Data Protection

The proposed amendments will render meaningful the protection for innovators under the data protection provisions of the Food and Drug Regulations and extend the period of data protection from five to eight years.

In Canada, generic competitors generally must demonstrate the bioequivalence of their product to an approved medicine before their product will be approved for sale by Health Canada. Generic competitors demonstrate this bioequivalence by comparing their product with the product of the innovator. Existing data protection provisions in the Food and Drug Regulations are intended to guarantee the confidentiality and non-use of an innovator’s data—and hence prevent a generic competitor from making the comparison—for a period of five years. The courts have interpreted the provisions so narrowly, however, as to be ineffective.

The proposed amendments would prohibit the granting of a notice of compliance to a party that directly or indirectly compares its drug to an innovator’s drug, if the comparison forms the basis on which the party seeks approval and if the medicinal ingredient in the party’s drug is identical to the medicinal ingredient in the innovator’s drug. This prohibition would last for a period of eight years from the first notice of compliance granted to the innovator for the drug in question. If the first notice of compliance to the innovator is based on studies that include pediatric studies, the period of prohibition is eight and a half years.

The deadline for filing submissions with the government of Canada on these proposed amendments was February 24, 2005. The government is assessing these submissions to determine whether to modify the proposed amendments and then promulgate them or whether to republish the proposed amendments if the changes that the government makes to them warrant republication.

Footnotes

2. S.O.R./1993-133. Available at http://laws.justice.gc.ca/en/p-4/sor-93-133/161377.html (last visited May 4, 2005).

3. C.R.C., c. 870. Available at http://laws.justice.gc.ca/en/f-27/c.r.c.-c.870/text.html (last visited May 2, 2005).

4. R.S.C. 1985, c. P-4. Available at http://laws.justice.gc.ca/en/p-4/91746.html (last visited May 4, 2005).

Mr. McCourt is a partner in the Intellectual Property Department in the Toronto office of Torys LLP.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions